Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telemedycyna Polska's revenue for the
three
months ended in Mar. 2026 was zł1.43 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was zł5.39 Mil.
Telemedycyna Polska's Revenue per Share for the
three
months ended in Mar. 2026 was zł0.11.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.45.
Warning Sign:
Telemedycyna Polska SA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Telemedycyna Polska was -13.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -19.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -7.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Telemedycyna Polska's highest 3-Year average Revenue per Share Growth Rate was 60.50% per year. The lowest was -19.40% per year. And the median was -2.75% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Telemedycyna Polska Revenue Related Terms
Telemedycyna Polska Revenue Historical Data
* Premium members only.
The historical data trend for Telemedycyna Polska's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Telemedycyna Polska's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telemedycyna Polska Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Telemedycyna Polska's Revenue distribution charts can be found below:
* The bar in red indicates where Telemedycyna Polska's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł5.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telemedycyna Polska (WAR:TMP) has a Revenue of zł5.39 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Telemedycyna Polska and its competitors.
Is Telemedycyna Polska's Revenue too high?
Telemedycyna Polska's current Revenue is zł5.39 Mil. Overall, Telemedycyna Polska has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telemedycyna Polska's Revenue compare to VEEV and BTSG?
Telemedycyna Polska's Revenue of zł5.39 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Telemedycyna Polska and its competitors. Telemedycyna Polska's current Revenue is zł5.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telemedycyna Polska stock overvalued right now?
Based on GuruFocus' analysis, Telemedycyna Polska (WAR:TMP) is currently considered Modestly Undervalued. The stock's GF Value™ is zł0.82, compared to a current price of zł0.65 — trading 20.7% below its estimated fair value. The current Revenue is zł5.39 Mil. Telemedycyna Polska's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Telemedycyna Polska (WAR:TMP), the current Revenue is zł5.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telemedycyna Polska (WAR:TMP) Overvalued in 2026?
Based on GuruFocus' analysis, Telemedycyna Polska stock appears to be undervalued.
The current stock price of zł0.65 is trading 20.7% below its estimated GF Value™ of zł0.82.
GuruFocus considers Telemedycyna Polska to be Modestly Undervalued.
Key valuation signals for WAR:TMP:
Revenue: zł5.39 Mil
GF Value™: zł0.82 vs. price of zł0.65 (20.7% below fair value)
No single metric tells the full story. See the WAR:TMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telemedycyna Polska SA offers telecardiology services for individual patients and medical facilities in Poland. The company offers cardiologic care services through telephone and Internet. The company also provides telemedical services to health centres.
28GF Score
Get the complete analysis for WAR:TMP
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:TMP has been successfully added to your 
